The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characteristics of breakthrough cancer pain in patients treated with fentanyl sublingual tablets: An analysis of two phase III trials.
S. Nalamachu
Research Funding - ICRE / Multicenter Trial
R. L. Rauck
Consultant or Advisory Role - AcelRx (U); BioDelivery Sciences International (U); Prostrakan (U)
Honoraria - BioDelivery Sciences International; Prostrakan
Research Funding - AcelRx; Archimedes; BioDelivery Sciences International; Endo Pharmaceuticals; Prostrakan
A. Yellowlees
Consultant or Advisory Role - Prostrakan
M. S. Wallace
Research Funding - Endo Pharmaceuticals
D. Hassman
No relevant relationships to disclose
G. Guillory
Employment or Leadership Position - Prostrakan
J. D. Howell
Employment or Leadership Position - Prostrakan